Byondis Showcases Novel ADC Technology at Cancer Research Meeting, Aiming to Overcome Therapeutic Resistance
Byondis, a biopharmaceutical company based in the Netherlands, is presenting its innovative antibody-drug conjugate (ADC) technology platforms at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The company is highlighting two platforms: an antifolate linker-drug platform and a phosphonate linker-drug platform. These platforms are designed to address resistance to current ADC treatments and provide new therapeutic options for cancer patients. The antifolate platform features a differentiated mechanism of action aimed at overcoming systemic side effects, while the phosphonate platform targets immune activation in the tumor microenvironment. Byondis' research emphasizes the potential of these platforms to deliver targeted cancer therapies with improved efficacy and reduced toxicity. 
